{"entity":{"id":"nct05918302","kind":"trial","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","aka":["LEVEL"],"tldr":"A phase 3 trial of 177Lu-edotreotide and everolimus in lung cancer, run by Grupo Espanol de Tumores Neuroendocrinos, now recruiting.","summary":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. is a phase 3, randomised interventional study registered as NCT05918302 by Grupo Espanol de Tumores Neuroendocrinos, with a registry enrolment figure of 170 participants, started 2023-10-27 and due to reach its primary completion in 2029-03. Interventions recorded: 177Lu-edotreotide; Everolimus. Conditions listed: Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: \"Patients who have histologically confirmed metastatic or locally advanced unresectable well/moderately differentiated; World Health Organization (WHO\\]) 2015 criteria; neuroendocrine tumor of lung (typical and atypical carcinoids) or thymus origin either functioning or non-functioning\". Sites: Belgium, France, Italy, Spain. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05918302","url":"https://clinicaltrials.gov/study/NCT05918302"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["itm-11","everolimus"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05918302","phase":"3","setting":"Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","enrolled":170,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05918302/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}